Therapeutic Potential of Silodosin for Chronic Prostatitis: Efficacy and Safety Insights
Therapeutic Potential of Silodosin for Chronic Prostatitis
DOI:
https://doi.org/10.54393/pjhs.v5i07.1883Keywords:
Silodosin, Clinical Efficacy, Chronic Prostatitis, SafetyAbstract
Chronic prostatitis is a common urological condition impacting men globally and poses a considerable clinical challenge due to its diverse symptoms and vague causes. The symptoms significantly affect patients' quality of life. Objective: To investigate the efficacy and safety of silodosin in men with chronic prostatitis who have not previously been treated with alpha-blockers for this condition. Methods: A quasi-experimental study was conducted from July 2022 to June 2023 at Niazi Welfare Foundation Teaching Hospital, Sargodha. Eighty-two patients with chronic prostatitis were treated with 4 mg of silodosin once daily and monitored for 12 weeks. Data collection commenced following IRB approval (NM&DC-IRB-43) and informed consent from all participants. Descriptive statistics were used to calculate the mean and standard deviation. Mean differences in NIH-CPSI score were computed through paired t-test at p-value < 0.05, using SPSS version 25.0. Results: Results show noticeable improvement in CP and NIH-CPSI scores following treatment. The change in symptoms of CP and NIH-CPSI score before and after silodosin indication were statistically significant (p < 0.05). Additionally, the treatment was well-tolerated, with minimum adverse events reported. Conclusions: Silodosin, a novel selective inhibitor of the α1A-adrenergic receptor, proved to be effective in treating chronic prostatitis without significant side effects.
References
Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology. 1999 Aug; 54(2): 229-33. doi: 10.1016/S0090-4295(99)00205-8. DOI: https://doi.org/10.1016/S0090-4295(99)00205-8
Yebes A, Toribio-Vazquez C, Martinez-Perez S, Quesada-Olarte JM, Rodriguez-Serrano A, Álvarez-Maestro M et al. Prostatitis: a review. Current urology reports. 2023 May; 24(5): 241-51. doi: 10.1007/s11934-023-01150-z. DOI: https://doi.org/10.1007/s11934-023-01150-z
Zhang J, Liang C, Shang X, Li H. Chronic prostatitis/chronic pelvic pain syndrome: a disease or symptom? Current perspectives on diagnosis, treatment, and prognosis. American journal of men's health. 2020 Jan; 14(1): 1557988320903200. doi: 10.1177/1557988320903200. DOI: https://doi.org/10.1177/1557988320903200
Sugimoto M, Hijikata Y, Tohi Y, Kuroda H, Takei M, Matsuki T et al. Low quality of life in men with chronic prostatitis-like symptoms. Prostate Cancer and Prostatic Diseases. 2022 Dec; 25(4): 785-90. doi: 10.1038/s41391-022-00559-w DOI: https://doi.org/10.1038/s41391-022-00559-w
Magistro G and Wagenlehner FM. Chronic prostatitis/chronic pelvic pain syndrome (NIH category III). Evidence‐Based Urology. 2018 Aug: 539-44. doi: 10.1002/9781119129875.ch47. DOI: https://doi.org/10.1002/9781119129875.ch47
Shah AA, Mannan A, Ayub M, Shafi N, Ali A, Raza ZA et al. Questionnaire Survey of Urologists Concerning Chronic Prostatitis and Chronic Pelvic Pain Syndrome. Esculapio Journal of SIMS. 2022 Jun; 18(2): 219-223. doi: doi.org/10.51273/esc22.2518222.
Pena VN, Engel N, Gabrielson AT, Rabinowitz MJ, Herati AS. Diagnostic and management strategies for patients with chronic prostatitis and chronic pelvic pain syndrome. Drugs & Aging. 2021 Oct; 38: 845-86. doi: 10.1007/s40266-021-00890-2. DOI: https://doi.org/10.1007/s40266-021-00890-2
Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P et al. Comprehensive overview of prostatitis. Biomedicine & Pharmacotherapy. 2017 Oct; 94: 1064-76. doi: 10.1016/j.biopha.2017.08.016. DOI: https://doi.org/10.1016/j.biopha.2017.08.016
Nickel JC. Is chronic prostatitis/chronic pelvic pain syndrome an infectious disease of the prostate?. Investigative and clinical urology. 2017 May; 58(3): 149-51. doi: 10.4111/icu.2017.58.3.149. DOI: https://doi.org/10.4111/icu.2017.58.3.149
Shoskes DA, Keslar KS, Gotwald P, Berglund R, Vij S. Neuroinflammatory gene expression in chronic prostatitis/chronic pelvic pain syndrome patients: insights into etiology and phenotype biology. Translational andrology and urology. 2021 Aug; 10(8): 3340–3347. doi: 10.21037/tau-21-387. DOI: https://doi.org/10.21037/tau-21-387
Magri V, Boltri M, Cai T, Colombo R, Cuzzocrea S, De Visschere P et al. Multidisciplinary approach to prostatitis. Archivio Italiano di Urologia e Andrologia. 2018; 90(4): 227-48. doi: 10.4081/aiua.2018.4.227. DOI: https://doi.org/10.4081/aiua.2018.4.227
DeWitt-Foy ME, Nickel JC, Shoskes DA. Management of chronic prostatitis/chronic pelvic pain syndrome. European Urology Focus. 2019 Jan; 5(1): 2-4. doi: 10.1016/j.euf.2018.08.027. DOI: https://doi.org/10.1016/j.euf.2018.08.027
Franz J, Kieselbach K, Lahmann C, Gratzke C, Miernik A. Chronic primary pelvic pain syndrome in men: differential diagnostic evaluation and treatment. Deutsches Ärzteblatt International. 2023 Jul; 120(29-30): 508-518. doi: 10.3238/arztebl.m2023.0036. DOI: https://doi.org/10.3238/arztebl.m2023.0036
Franco JV, Turk T, Jung JH, Xiao YT, Iakhno S, Tirapegui FI et al. Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database of Systematic Reviews. 2019 Oct; (10). 10.1002/14651858.CD012552.pub2. DOI: https://doi.org/10.1002/14651858.CD012552.pub2
Su ZT, Zenilman JM, Sfanos KS, Herati AS. Management of chronic bacterial prostatitis. Current urology reports. 2020 Jul; 21:1-8. doi: 10.1007/s11934-020-00978-z. DOI: https://doi.org/10.1007/s11934-020-00978-z
Deng W, Du X, Zhou W, Mei X, Tian Y, Chen L et al. Systematic review and meta-analysis: α-adrenergic receptor blockers in chronic prostatitis. Annals of Palliative Medicine. 2021 Sep; 10(9): 9870878-9878. doi: 10.21037/apm-21-2160. DOI: https://doi.org/10.21037/apm-21-2160
Villa L, Capogrosso P, Capitanio U, Martini A, Briganti A, Salonia A et al. Silodosin: an update on efficacy, safety and clinical indications in urology. Advances in Therapy. 2019 Jan; 36: 1-8. doi: 10.1007/s12325-018-0854-2. DOI: https://doi.org/10.1007/s12325-018-0854-2
Krakhotkin DV, Chernylovskyi VA, Bakurov EE, Sperl J. Evaluation of influence of the UPOINT-guided multimodal therapy in men with chronic prostatitis/chronic pelvic pain syndrome on dynamic values NIH-CPSI: a prospective, controlled, comparative study. Therapeutic Advances in Urology. 2019 Jun; 11: 1756287219857271. doi: 10.1177/1756287219857271. DOI: https://doi.org/10.1177/1756287219857271
Gul A, Coban S, Turkoglu AR, Guzelsoy M, Ozturk M, Kankilic NA. Comparative efficacy and safety profile of 4 vs 8 mg of silodosin once daily usage in patients with benign prostatic hyperplasia–related lower urinary tract symptoms divided into subgroups according to International Prostate Symptom Score severity. Prostate International. 2020 Dec; 8(4): 152-7. doi: 10.1016/j.prnil.2020.04.002. DOI: https://doi.org/10.1016/j.prnil.2020.04.002
Creta M, Cornu JN, Roehrborn CG, Agrò EF, Montorsi F, Longo N et al. Clinical efficacy of silodosin in patients with severe lower urinary tract symptoms related to benign prostatic obstruction: a pooled analysis of Phase 3 and 4 trials. European Urology Focus. 2021 Mar; 7(2): 440-3. doi: 10.1016/j.euf.2020.01.014. DOI: https://doi.org/10.1016/j.euf.2020.01.014
Jindan L, Xiao W, Liping X. Evolving role of silodosin for the treatment of urological disorders–A narrative review. Drug Design, Development and Therapy. 2023 Dec: 2861-84. doi: 10.2147/DDDT.S373659. DOI: https://doi.org/10.2147/DDDT.S373659
Cho KJ, Lee JZ, Song YS, Choi JB, Kim DK, Kim YT et al. Evaluating the efficacy and safety of silodosin on nocturia in patients with benign prostatic hyperplasia: a multicenter, prospective, open-label, single-arm, Phase IV trial. Urology. 2018 Nov; 121: 153-7. doi: 10.1016/j.urology.2018.07.008. DOI: https://doi.org/10.1016/j.urology.2018.07.008
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments